CD14 and myeloproliferative disorder: With respect to differentiation markers, we found that most patients’ samples treated with AG221 showed upregulation of either the erythroid marker CD235a (Figure 8B) or the myeloid marker CD14, consistent with restored differentiation in JAK2/IDH2-mutant MPN and AML cells (Figure 8C).